Mesenchymal Stromal Cells

WJ-MSCs, cells at the heart of StemInov’s innovation, are a particular type of adult MSC, of which several types have been described according to their location in the body and their origin in foetal (Wharton’s jelly) or adult tissues (two main sources are bone marrow (BM), adipose tissue (AT)).

Thanks to their properties (figure below) Mesenchymal stem cells (MSCs) are a critical raw material for many regenerative medicine products, including cell-based therapies, engineered tissues, or combination products. Indeed, MSCs modulate the host immune systems, e.g., by secreting various trophic factors. Thereby, they reduce inflammation, promote neoangiogenesis, and prevent apoptosis and fibrosis. Additionally, they stimulate local stem cells to develop new tissue.

Furthermore, as they do not express major histocompatibility complex (MHC) class II molecules and have only low levels of MHC class I, MSCs are poorly immunogenic cells and therefore potentially usable in an allogeneic situation (where the donor is a different person from the patient), which makes them particularly attractive for clinical use.

WJ-MSCs have intrinsic properties that hold great promise for the treatment of infectious and inflammatory diseases, including septic shock. Indeed, these cells have a triple mechanism of action:

  • Unique modulation of immunity and inflammation through pro- or anti-inflammatory behavior depending on the environment in which they are located,
  • Direct and indirect antibacterial by effect on phagocytic cells capable of eliminating the pathogenic microorganisms responsible for the infection,
  • Targeting and migrating to injured sites for tissue repair.

The Mesenchymal Stromal Cells (MSC) field is a validated and de-risked therapeutic modality…

1990s

MSC first clinical trials

2024

First US MSC approval (Ryoncil®,)

2025+

Commercial ramp-up

$4B

Global MSC market, 2025

13%

CAGR (2026–2035)²

First approved MSC therapy

Ryoncil (Mesoblast) — steroid-refractory acute GvHD,· ~$120M FY2026 sales

2 approved MSC products

North America / EU

Ryoncil · Holoclar

10 locally approved MSC products

Asia & emerging markets

Late-stage (Phase III) programs

  • Mesoblast — chronic low back pain / heart failure
  • Stempeutics — diabetic foot ulcer
  • Medipost — knee cartilage defects
  • Mesoblast — acute GvHD

Cell sources¹

Bone MarrowUmbilical CordAdipose TissueOther

Treatment type¹

Off-the-shelf (allogenic)Personalized (autologous)

¹ Source: Mab Design external study – on data room
² Source: Grand View Research 2023

Adult MSCBone marrow or adipose tissue
Wharton Jelly MSC
Umbilical cord
Sourcing
Adult MSC
Bone marrow or adipose tissue
Complex & invasive sampling
Wharton Jelly MSC
Umbilical cord
Sampling easy, frequent and rich in MSCs
Batch to batch consistency
Adult MSC
Bone marrow or adipose tissue
Lack of homogeneity between samples (age of the donor)
Wharton Jelly MSC
Umbilical cord
Homogeneous batches
Proliferation
Adult MSC
Bone marrow or adipose tissue
++
Wharton Jelly MSC
Umbilical cord
+++
Immunization
Adult MSC
Bone marrow or adipose tissue
YES
Wharton Jelly MSC
Umbilical cord
NO
Therapeutic potential
Adult MSC
Bone marrow or adipose tissue
+
Wharton Jelly MSC
Umbilical cord
+++

WhartSep® mechanism of action is based on three main actions

1 DRUG FOR 3 ACTIONS

1

Manage & modulate inflammation

Modulate pro-inflammatory cytokines and promote secretion of anti-inflammatory cytokines

Balance innate and adaptive immunity

2

Lower the infective load

Enhance bacterial clearance by producing antimicrobial peptides

Cell-to-cell contact boosts monocyte and alveolar macrophage phagocytosis, without excessive inflammation

3

Protect the lungs

Restore alveolar epithelial fluid clearance

Protect endothelial barriers

Mitigate vascular permeability and edema

Partners

R&D

Support

Labels